Imaging and Tissue Correlates to Optimize Management of Glioblastoma

影像学和组织相关性可优化胶质母细胞瘤的治疗

• 批准号: 8721854
• 负责人: Susan M Chang
• 金额: $ 210.17万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-27 至 2018-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8721854
• 关键词: Address; Aftercare; Anatomy; Biological; Biological Assay; Biological Markers; Biopsy; Biostatistics Core; Brain; Brain Neoplasms; Carbon; Caring; Characteristics; Choline; Clinical; Clinical Services; Clinical Trials; Data; Development; Diagnosis; Disease; Drug Delivery Systems; Drug effect disorder; Effectiveness; Epigenetic Process; Evaluation; Evolution; Gene Expression Profile; Genetic; Genome; Genomics; Glioblastoma; Goals; Heterogeneity; Histologic; Image; Image Analysis; Imaging Techniques; Individual; Induced Mutation; Inositol; Lesion; Link; Magnetic Resonance Spectroscopy; Malignant - descriptor; Measures; Medical; Metabolic; Molecular Profiling; Monitor; Outcome; Patient Care; Patients; Physiological; Prognostic Factor; Program Research Project Grants; Property; Pyruvate; Pyruvate Metabolism Pathway; Recurrence; Recurrent tumor; Research; Resource Sharing; Resources; Role; Sampling; Services; Technology; Therapeutic Agents; Time; Tissue Sample; Tissues; Tumor Burden; base; clinical care; clinically relevant; design; effective therapy; epigenome; exome; imaging modality; improved; in vivo; molecular imaging; neuro-oncology; non-invasive imaging; novel; novel strategies; programs; resistance mechanism; response; spectroscopic imaging; treatment effect; treatment response; treatment strategy; tumor; tumor growth; tumor progression

DESCRIPTION (provided by applicant): The overall goal of the new P01 is to integrate advances in physiologic and metabolic imaging with tissue biomarkers in order to optimize the management of patients with glioblastoma. This will be achieved by characterizing the evolution of changes in imaging, genetic and epigenetic profiles from the time of initial presentation until presumed tumor progression. The information obtained will be applied to determine whether it is possible to tailor treatment strategies to individual patients and will be used in combination with hyperpolarized C-13 metabolic imaging to inform on the early response to therapeutic agents. The results of these studies will address critical challenges in the field of Neuro-Oncology and have the potential to make a significant impact upon the management of patients with brain tumors. Three highly integrated and synergistic projects are planned: Project 1: Improved management of GBM by integrated imaging and tissue analysis. Project 2: Image guided genome-epigenome analysis of tumor heterogeneity and evolution and Project 3: Hyperpolarized carbon 13 MRSI monitoring of pyruvate metabolism to assess drug action. The overall specific aims of the P01 are: 1) To accurately define tumor burden in the post treated setting. Projects 1 and 3 will assess the role of novel imaging techniques to assess tumor burden. 2) To characterize intratumoral heterogeneity (imaging parameters, histologic characteristics, genetic/epigenetic features) and the effect on treatment response, tumor evolution and clinical outcome. Projects 1 and 2 will be integrated to accomplish this aim. 3) To assess early response to therapy to assist with treatment decisions. Projects 1 and 3 will accomplish this aim through the clinical development and application of hyperpolarized C-13 imaging in conjunction with physiological and metabolic imaging techniques. Three shared resources (Administrative and Clinical Services Core, Biospecimen and Biostatistics Core and the Imaging Core) will provide key services that are essential for the Projects to accomplish their aims.

描述（由申请人提供）：新P01的总体目标是将生理和代谢成像与组织生物标志物的进展结合起来，以优化胶质母细胞瘤患者的管理。这将通过描述从最初的表现到假定的肿瘤进展的成像、遗传和表观遗传谱变化的演变来实现。获得的信息将用于确定是否有可能为个别患者量身定制治疗策略，并将与